B

Biogen

Profile managed by Bizz Id
United States 1978

Description

Biotechnology company developing medicines in neurology, immunology and rare diseases. Its portfolio combines monoclonal antibodies, interferons, antisense oligonucleotides and small molecules.

Products

7 products
Dapirolizumab pegol

Phase 3. Anti-CD40L; systemic lupus erythematosus (SLE).

Under development

Finished product (FDF)

Verified on 2026-10-21

Dapirolizumab pegol: see suppliers →

Felzartamab

Phase 3. Anti-CD38; antibody-mediated rejection, IgA nephropathy, primary membranous nephropathy (Phase 3); microvascular inflammation (Phase 2).

Under development

Finished product (FDF)

Verified on 2026-10-21

Felzartamab: see suppliers →

Interferon beta-1a

Brand: Avonex. Neuroscience.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Interferon beta-1a: see suppliers →

Lecanemab

Brand: Leqembi (lecanemab-irmb). Partnered product, collaboration with Eisai. Anti-Aβ antibody. In development: presymptomatic Alzheimer's disease (Phase 3).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Lecanemab: see suppliers →

Litifilimab

Phase 3. Anti-BDCA2; systemic lupus erythematosus and cutaneous lupus erythematosus.

Under development

Finished product (FDF)

Verified on 2026-10-21

Litifilimab: see suppliers →

Natalizumab

Brand: Tysabri. Neuroscience.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Natalizumab: see suppliers →

Peginterferon beta-1a

Brand: Plegridy. Neuroscience.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Contact company

Register for free to see this company’s contact details and get in touch.

Register - Free